Maspin expression in prostate tumor elicits host anti-tumor immunity

Sijana H Dzinic1, Kang Chen2, Archana Thakur3

  • 1Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan. Tumor Biology and Microenvironment Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.

Oncotarget
|November 7, 2014
PubMed

Insights

The tumor suppressor maspin enhances anti-tumor immunity by activating neutrophils and B cells. Maspin expression in tumors promotes immune responses, leading to reduced tumor incidence and better cancer prognosis.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Maspin, an epithelial-specific tumor suppressor, exhibits anti-tumor effects by inhibiting tumor growth, invasion, and metastasis.
  • Its mechanism involves histone deacetylase inhibition, maintaining epithelial phenotype and affecting stromal responses like extracellular matrix degradation, fibrosis, and angiogenesis.

Purpose of the Study:

  • To investigate the biological effects of maspin on the tumor host immune response.
  • To elucidate maspin's role in modulating host immunity against tumors.

Main Methods:

  • Utilized an athymic nude mouse model with xenogeneic human prostate cancer cells.
  • Analyzed systemic and intratumoral neutrophil maturation, activation, and antibody-dependent cytotoxicity.
  • Assessed peritumoral lymphangiogenesis and xenograft tumor incidence.

Main Results:

  • Maspin expression in tumor cells induced neutrophil- and B cell-dependent host tumor immunogenicity.
  • Observed increased neutrophil maturation, activation, and antibody-dependent cytotoxicity in mice with maspin-expressing tumors.
  • Demonstrated decreased peritumoral lymphangiogenesis and a significant reduction in xenograft tumor incidence.

Conclusions:

  • Maspin plays a novel role in directing host immunity towards tumor elimination.
  • Maspin expression correlates with better cancer prognosis and reduced tumor incidence.
  • Findings suggest potential for maspin-based cancer immunotherapies.